GlassScriptPhysician profile
William Sims Buice
NPI 1982658837
$3,599.49
in general payments reported to CMS, 2019-2025
78 companies · $578 in 2025
The $578 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $481 · 2020: $288 · 2021: $490 · 2022: $546 · 2023: $323 · 2024: $895 · 2025: $578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,795.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $265.70 | 2021-2025 | Keytruda, Lynparza |
| Eisai INC. | $217.07 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $163.35 | 2019-2025 | Calquence, Tagrisso |
| Novartis Pharmaceuticals Corporation | $142.52 | 2019-2024 | |
| Boston Scientific Corporation | $124.70 | 2022-2024 | Spyglass Discover |
| Janssen Biotech, INC. | $124.49 | 2019-2025 | Erleada |
| Medical Device Business Services, INC. | $115.66 | 2021 | |
| Davol INC. | $108.91 | 2020-2025 | Phasix Mesh |
| Incyte Corporation | $104.80 | 2019-2025 | Monjuvi, Zynyz, Pemazyre |
| Seagen INC. | $97.75 | 2019-2023 | Padcev |
| Focal Therapeutics, INC. | $93.61 | 2019 | |
| Celgene Corporation | $90.28 | 2019-2025 | Reblozyl |
| Becton, Dickinson and Company | $88.84 | 2024 | |
| Amgen INC. | $84.74 | 2019-2022 | |
| Atricure, INC. | $72.61 | 2021 |
Show all 78 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Buice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.